Monday, April 4, 2016 5:19:00 AM PDT | VentureDeal
Pittsburgh, Pennsylvania -- Neurological technology company Cognition Therapeutics has received nearly $3.5 million in new debt investment, according to an SEC regulatory filing.
Cognition is developing therapeutics to treat patients with Alzheimer's disease and other related neurodegenerative disorders. Investors in the financing were not disclosed, nor was how the company intends to use the funding proceeds. A total of 41 investors participated in the offering. Cognition is still seeking $1 million in additional debt investment, according to the filing. Minimum investment size per investor was listed as $647.
Email Page | Print Page
Want unlimited access to the complete database with thousands of technology companies, VCs and transactions for only $25 per month?
Start your Free 14 Day Trial now – no obligation or credit card required.
